Understanding the US Biosecure Act's Impact on the Indian Pharma Industry
Overview of the US Biosecure Act
The US Biosecure Act passed on September 9, aims to limit US biopharmaceutical reliance on China. This legislative shift prohibits collaborations with five Chinese companies to foster growth in US and Indian markets.
Implications for Indian CDMO Players
- Indian CDMO companies like Divi's Labs and Laurus Labs are set to benefit from increased inquiries as US firms seek alternatives to Chinese manufacturers.
- The act impacts up to 120 US biopharmaceutical drugs, creating opportunities for Indian players.
Market Growth and Forecast
The CDMO market is growing, driven by biotech companies needing support without heavy investments in infrastructure. The US Biosecure Act positions India as a favorable destination for outsourcing.
- India's CDMO market projected to grow from $19.63 billion in 2023 to $44.69 billion by 2029.
- Supported by government incentives and increasing foreign investment.
This act marks a pivotal moment for the Indian pharma sector, as the industry braces for substantial growth amid a shifting global landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.